We use cookies to customise content for your viewing and for analytics. If you continue to browse this website, we will assume that you are happy to receive all our cookies. For further information, please read our cookie policy.
Bibi, R., Bankole, N. D. A., Donnard, B., Giubbolini, F., Boucherit, J., Barrot, V., Herbreteau, D., Ifergan, H., Janot, K., Boulouis, G., & Bala, F.
Safety and Efficacy of Surpass Evolve Flow Diverter for Intracranial Aneurysms: A Study of 116 Patients
80.4%
Neck remnant or complete occlusion (OKM C-D) rate at 6 months
75.6%
Complete occlusion (OKM D) rate at 3 months
| Number of patients | 116 |
| Number of aneurysms | 120 |
| Major morbidity and mortality | 0.8% (1/107) |
| In-stent stenosis (25-49%) | 1.9% (2/107) |
| In-stent stenosis (≥50%) | 0.9% (1/107) |
Neuroradiology Journal | 2024
Bibi R, Bankole NDA, Donnard B, et al. Safety and efficacy of Surpass Evolve Flow diverter for intracranial aneurysms: A study of 116 patients. Neuroradiol J. 2024;37(2):184-191. doi:10.1177/19714009231224408
Stryker or its affiliated entities own, use, or have applied for the following trademarks or service marks: Stryker, Surpass Evolve. All other trademarks are trademarks of their respective owners or holders.
Information contained herein for use outside the US only.
AP004692 v1.0